Kamila Saramak

Dr. Kamila Saramak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
ADAnna Dunalska
Anna Dunalska
KSKamila Saramak
Kamila Saramak
Natalia SzejkoNatalia Szejko
Natalia Szejko
Multiple sclerosis (MS) is a chronic, progressive neuroinflammatory disease with a complex pathophysiological background. A variety of diverse factors have been attributed to the propagation of inflammation and neurodegeneration in MS, mainly genetic, immunological, and environmental factors such as vitamin D deficiency, infections, or hormonal disbalance. Recently, the importance of the gut-brain axis for the development of many neurological conditions, including stroke, movement disorders, and neuroinflammatory disorders, has been postulated. The purpose of our paper was to summarize current evidence confirming the role of the gut microbiome in the pathophysiology of MS and related disorders, such as neuromyelitis optica spectrum disorder (NMO-SD). For this aim, we conducted a systematic review of the literature listed in the following databases: Medline, Pubmed, and Scopus, and were able to identify several studies demonstrating the involvement of the gut microbiome in the pathophysiology of MS and NMO-SD. It seems that the most relevant bacteria for the pathophysiology of MS are those belonging to Pseudomonas, Mycoplasma, Haemophilus, Blautia, Dorea, Faecalibacterium, Methanobrevibacter, Akkermansia, and Desulfovibrionaceae genera, while Clostridium perfringens and Streptoccocus have been demonstrated to play a role in the pathophysiology of NMO-SD. Following this line of evidence, there is also some preliminary data supporting the use of probiotics or other agents affecting the microbiome that could potentially have a beneficial effect on MS/NMO-SD symptoms and prognosis. The topic of the gut microbiome in the pathophysiology of MS is therefore relevant since it could be used as a biomarker of disease development and progression as well as a potential disease-modifying therapy.

19 June 2024
Verified
Book Chapter
Open access
PDF file
KSKamila Saramak
Kamila Saramak
Natalia SzejkoNatalia Szejko
Natalia Szejko
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a selective loss of motor neurons from the spinal cord, brainstem and motor cortex. With a prevalence of about 5.5–9.9 per 100,000 persons, ALS is the most common form of motor neuron disease (MND). Although the mechanisms underlying the pathophysiology of this condition are not yet fully understood, it is believed that excitotoxicity, inflammation and oxidative stress play an important role in selective motor neuron death. Despite intensive research, up to this point no cure for ALS has been identified. There is increasing evidence that cannabinoids, due to their anti-glutamatergic and anti-inflammatory actions, may show neuroprotective effects in ALS patients and slow the progression of the disease. Furthermore, cannabis-based medicine may be useful in managing symptoms like pain, spasticity or weight loss. The aim of this chapter is to summarize the current state of research regarding the efficacy and safety of medical cannabis in the treatment of ALS.

3 June 2025 in Allergies
Verified
Journal Article
Open access
PDF file
KSKamila Saramak
Kamila Saramak
The interplay between allergic diseases and neurological disorders has gained increasing attention over the past decades, highlighting potential shared pathophysiological pathways. Allergic diseases, including asthma, eczema, and allergic rhinitis, are characterized by chronic inflammation and immune dysregulation, which may impact the pathogenesis of certain neurological conditions. Emerging evidence suggests that conditions such as multiple sclerosis (MS), migraine, epilepsy, neurodegenerative diseases, and neurodevelopmental disorders may be influenced by systemic inflammation and altered immune responses associated with allergies. The purpose of this paper is to provide an overview of current epidemiological evidence suggesting a relationship between allergic and neurological diseases. Understanding the complex interactions between allergic and neurological diseases could provide new insights into their aetiology and reveal novel therapeutic targets, paving the way for integrated approaches in managing comorbid allergic and neurological conditions, ultimately improving patient outcomes and quality of life.

28 December 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
DRDorota Różański
Dorota Różański
Stanisław SzlufikStanisław Szlufik
Stanisław Szlufik
RTRyszard Tomasiuk
Ryszard Tomasiuk
LMLukasz Milanowski
Lukasz Milanowski
MFMonika Figura
Monika Figura
DKDariusz Koziorowski
Dariusz Koziorowski
Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker elevated in cardiovascular diseases. The aim of this 3-year follow-up prospective study was to evaluate suPAR levels in patients with a first ischemic stroke in correlation with CRP, PCT, NT-proCNP and endothelin 1-21 and to investigate the impact of suPAR on the outcome. Fifty-one patients (mean age 73.7+ = 11.9 years, 26 female and 25 male) were included. Samples were collected on the first (suPAR 1), third (suPAR 3) and seventh days after stroke onset (suPAR 7). Plasma samples were analyzed using ELISA. A phone interview was conducted to collect follow-up information after 24 and 36 months (modified Rankin Scale, mRS). A positive correlation between suPAR levels and other inflammatory biomarkers (except endothelin 3) was observed. A positive correlation between suPAR 3 and mRS score at 24 months was observed (p = 0.042). The logistic regression model revealed no significant effect of suPAR on death occurrence in the first 24 months: suPAR 1 (p = 0.8794), suPAR 3 (p = 0.2757), and suPAR 7 (p = 0.3652). The suPAR level is a potential inflammatory marker in ischemic stroke, and there is a correlation with other markers. There is no major impact on mortality. However, the suPAR level is associated with a degree of disability or dependence in daily activities 2 years after a stroke.

5 July 2025
Verified
Book Chapter
Closed access
PDF file
ADAnna Dunalska
Anna Dunalska
KSKamila Saramak
Kamila Saramak
KŚKatarzyna Śmiłowska
Katarzyna Śmiłowska
Natalia SzejkoNatalia Szejko
Natalia Szejko

11 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Natalia SzejkoNatalia Szejko
Natalia Szejko
AAAli Abusrair
Ali Abusrair
TPTomasz Pasierski
Tomasz Pasierski
SSSimon Schmitt
Simon Schmitt
CCCatharina Cramer
Catharina Cramer
Kirsten Müller-VahlKirsten Müller-Vahl
Kirsten Müller-Vahl
Placebo, nocebo, and lessebo effects are very frequent in patients with both neurological and psychiatric disorders. Interestingly, the neural mechanisms underlying placebo effects have been found to be the same as or similar to mechanisms targeted by active pharmaceutical interventions for many of these disorders. In the case of functional neurological disorders (FNDs), there are shared neural substrates between the central nervous system “placebo network” and the dysfunctional networks implicated in the pathophysiology. These networks are primarily involved in emotion regulation, stress responses, and the sense of self-agency. Therefore, placebo effects have also been discussed as therapeutic interventions in FNDs. Such an approach, however, has a variety of ethical implications evolving around informed consent, autonomy, nonmaleficence, beneficence, and justice. In this paper, we discuss the use of placebo, nocebo, and lessebo in FNDs as well as related ethical issues. Overall, the use of placebo in FNDs is currently still considered controversial both for diagnostic as well as therapeutic purposes. Although it is a safe and almost unique intervention, its use violates the core principles of medical ethics and doctor–patient interactions involving autonomy or openness in the therapeutic relationship.